Cochrane

What are the benefits and harms of immunoglobulin for people with myasthenia gravis?

Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...

First drug treatment for sleep apnea may be within reach

The drug sulthiame reduces the number of breathing pauses and improves sleep quality in patients with obstructive sleep apnea, according to a European clinical study in which the University of ...
Le Lézard

PADCEVtm Plus KEYTRUDAtm, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Ophthalmology Times

Treating myopia today: US-focused treatments, challenges, and global insights

Pediatric progressive myopia is a growing global public health concern, linked to serious ocular complications including ...
BMJ

Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist

Treating oncologists have a high index of suspicion for irAEs and a low threshold for initiating treatment. The role of the neurologist ... worsening symptoms or new manifestations. Care of long-term ...